Growth rate-corrected (GR) dose-response metrics across a panel of 71 breast cancer cell lines treated with a library of small molecule and antibody perturbagens. Dataset 1 of 4: Relative cell counts and normalized growth rate inhibition values across technical replicates. - Dataset (ID:20268)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Clinical Subtype | Transcriptional Subtype | Small Molecule | Antibody | Perturbagen Target | Perturbagen Class | Perturbagen Concentration | Perturbagen Conc Unit | Biological Replicate ID | Relative Cell Count | Normalized Growth Rate Inhibition Value | Nominal Division Rate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| BT-549 | TNBC | Basal B | Lapatinib | EGFR/HER2 | ErbB | 0.667 | uM | 5909.098 | 1.0129 | 1.0098 | 2.6253 | |
| BT-549 | TNBC | Basal B | Lapatinib | EGFR/HER2 | ErbB | 3.33 | uM | 5909.098 | 0.9031 | 0.9239 | 2.6253 | |
| BT-549 | TNBC | Basal B | Lapatinib | EGFR/HER2 | ErbB | 16.7 | uM | 5909.098 | 0.8463 | 0.8768 | 2.6253 | |
| BT-549 | TNBC | Basal B | Lapatinib | EGFR/HER2 | ErbB | 0.0000427 | uM | 5910.098 | 1.0649 | 1.0396 | 3.2046 | |
| BT-549 | TNBC | Basal B | Lapatinib | EGFR/HER2 | ErbB | 0.000213 | uM | 5910.098 | 1.0655 | 1.0400 | 3.2046 | |
| BT-549 | TNBC | Basal B | Lapatinib | EGFR/HER2 | ErbB | 0.00107 | uM | 5910.098 | 1.0414 | 1.0255 | 3.2046 | |
| BT-549 | TNBC | Basal B | Lapatinib | EGFR/HER2 | ErbB | 0.00533 | uM | 5910.098 | 1.1075 | 1.0647 | 3.2046 | |
| BT-549 | TNBC | Basal B | Lapatinib | EGFR/HER2 | ErbB | 0.0267 | uM | 5910.098 | 1.0227 | 1.0141 | 3.2046 | |
| BT-549 | TNBC | Basal B | Lapatinib | EGFR/HER2 | ErbB | 0.133 | uM | 5910.098 | 1.0070 | 1.0044 | 3.2046 | |
| BT-549 | TNBC | Basal B | Lapatinib | EGFR/HER2 | ErbB | 0.667 | uM | 5910.098 | 1.0675 | 1.0412 | 3.2046 | |
| BT-549 | TNBC | Basal B | Lapatinib | EGFR/HER2 | ErbB | 3.33 | uM | 5910.098 | 0.9422 | 0.9632 | 3.2046 | |
| BT-549 | TNBC | Basal B | Lapatinib | EGFR/HER2 | ErbB | 16.7 | uM | 5910.098 | 0.9152 | 0.9455 | 3.2046 | |
| CAMA-1 | HR+ | Luminal | Lapatinib | EGFR/HER2 | ErbB | 0.0000427 | uM | 5911.098 | 0.9504 | 0.9067 | 1.0659 | |
| CAMA-1 | HR+ | Luminal | Lapatinib | EGFR/HER2 | ErbB | 0.000213 | uM | 5911.098 | 0.9734 | 0.9500 | 1.0659 | |
| CAMA-1 | HR+ | Luminal | Lapatinib | EGFR/HER2 | ErbB | 0.00107 | uM | 5911.098 | 0.9805 | 0.9634 | 1.0659 | |
| CAMA-1 | HR+ | Luminal | Lapatinib | EGFR/HER2 | ErbB | 0.00533 | uM | 5911.098 | 0.9780 | 0.9588 | 1.0659 | |
| CAMA-1 | HR+ | Luminal | Lapatinib | EGFR/HER2 | ErbB | 0.0267 | uM | 5911.098 | 0.9838 | 0.9697 | 1.0659 | |
| CAMA-1 | HR+ | Luminal | Lapatinib | EGFR/HER2 | ErbB | 0.133 | uM | 5911.098 | 0.9787 | 0.9600 | 1.0659 | |
| CAMA-1 | HR+ | Luminal | Lapatinib | EGFR/HER2 | ErbB | 0.667 | uM | 5911.098 | 0.9852 | 0.9723 | 1.0659 | |
| CAMA-1 | HR+ | Luminal | Lapatinib | EGFR/HER2 | ErbB | 3.33 | uM | 5911.098 | 0.9953 | 0.9911 | 1.0659 | |
| CAMA-1 | HR+ | Luminal | Lapatinib | EGFR/HER2 | ErbB | 16.7 | uM | 5911.098 | 0.9576 | 0.9203 | 1.0659 | |
| CAMA-1 | HR+ | Luminal | Lapatinib | EGFR/HER2 | ErbB | 0.0000427 | uM | 5912.098 | 0.9923 | 0.9855 | 1.0559 | |
| CAMA-1 | HR+ | Luminal | Lapatinib | EGFR/HER2 | ErbB | 0.000213 | uM | 5912.098 | 0.9507 | 0.9064 | 1.0559 | |
| CAMA-1 | HR+ | Luminal | Lapatinib | EGFR/HER2 | ErbB | 0.00107 | uM | 5912.098 | 0.9708 | 0.9446 | 1.0559 | |
| CAMA-1 | HR+ | Luminal | Lapatinib | EGFR/HER2 | ErbB | 0.00533 | uM | 5912.098 | 1.0305 | 1.0578 | 1.0559 |